Dominik T.
- Country
- Sweden
- Department
- Department of Pediatric Hematology, Oncology and Immunology
Research Overview
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Evaluation of Non-Total Body Irradiation Conditioning Regimens with Fludarabine, Thiotepa, and Busulfan in Pediatric Acute Lymphoblastic Leukemia Transplantation
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.
Data & Insights
Has run more than one trial at 70 of 177 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating acute lymphoblastic leukemia, with particular expertise in managing cases involving Philadelphia chromosome-positive variants of the disease.
- Pediatric leukemia treatment protocols
- Philadelphia chromosome-positive ALL management
- Risk-stratified therapy approaches
Their research encompasses innovative therapeutic strategies for different risk categories of ALL patients.
Stem Cell Transplantation
The investigator focuses on allogeneic stem cell transplantation approaches for children and adolescents with acute lymphoblastic leukemia, exploring various conditioning regimens.
- Alternative conditioning protocols
- HLA-matched donor transplantation
- Pediatric transplant outcomes
Their work includes evaluation of both traditional and non-total body irradiation containing conditioning methods.
Pediatric Oncology
The investigator's expertise extends to specialized treatment approaches for childhood and adolescent leukemia, with emphasis on age-specific therapeutic considerations.
- Age-adapted treatment protocols
- Long-term survival outcomes
- Risk factor assessment
Their research addresses specific therapeutic needs of different age groups in pediatric leukemia treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.